IMMUNOCHEMICAL STRUCTURE/FUNCTION OF APOLIPOPROTEIN A-I
Project Number1R01HL043815-01A1
Contact PI/Project LeaderCURTISS, LINDA K
Awardee OrganizationSCRIPPS RESEARCH INSTITUTE, THE
Description
Abstract Text
Apolipoprotein (apo) A-I is the major apoprotein of plasma high density
lipoproteins (HDL). Plasma lipoproteins play pivotal roles in cholesterol
metabolism and are important factors for identifying those people at risk
for atherosclerosis, stroke and cardiovascular disease. Individuals with
high levels of circulating HDL are at lower risk for the complications of
atherosclerosis. Numerous functions of apo A-I have been identified that
contribute to its beneficial properties. These include the capacity of apo
A-I to: 1) activate the enzyme that esterifies cholesterol in plasma,
lecithin: cholesterol acyl transferase (LCAT), b) mediate cholesterol
delivery to steroidogenic tissues, c) facilitate cholesterol egress from
certain nonhepatic peripheral cells such as the cholesteryl ester loaded
macrophage (e.g., the foam cells of the atherosclerotic lesion), and d)
enhance fibrinolysis. Thus, apo A-I plays an important role in vascular
biology and cholesterol metabolism. The primary structure of apo A-I is
known, however, specific regions of apo A-I that are responsible for
carrying out these functions are largely unknown. Using an immunochemical
approach, the relationship between apoprotein structure and function will
be explored. Four functions will be studied including LCAT activation,
cholesterol delivery to steroidogenic cells, cholesterol unloading from
macrophages, and the enhancement of fibrinolysis. An existing panel of apo
A-I-specific monoclonal antibodies, which are directed towards unique
regions on apo A-I, will be screened for their ability to block each of
these apo A-I functions. When antibodies are found that interfere with a
particular function, the fragments that represent the functionally
important regions of apo A-I will be tested for their ability to either
mimic or block apo A-I function. These studies will verify the hypothesis
that specific structural regions on apo A-I can be identified that are
responsible for each of its many functions. Furthermore, the successful
completion of these studies will begin to provide detailed information
regarding the specificity mechanism and physiologic importance of the
activation of LCAT, cellular interactions, and the enhancement of
fibrinolysis by apo A-I.
No Sub Projects information available for 1R01HL043815-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HL043815-01A1
Patents
No Patents information available for 1R01HL043815-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HL043815-01A1
Clinical Studies
No Clinical Studies information available for 1R01HL043815-01A1
News and More
Related News Releases
No news release information available for 1R01HL043815-01A1
History
No Historical information available for 1R01HL043815-01A1
Similar Projects
No Similar Projects information available for 1R01HL043815-01A1